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ABSTRACT

This work attempts to detect hepatitis C viral (Hep CV) NS3-4A protease and prostate
specific antigen (PSA) proteins using electrochemical methods. The sensing probes used
in detecting these biological markers are their inhibitory peptides. The inhibitory peptide
for the hepatitis C viral NS3-4A protease is Asp-Glu-Ile-Val-Pro-Nva with an IC50 o f 7.5
pM and the inhibitory peptide for prostate specific antigen is the peptide Ser-Lys-SerLys-Ser-Lys-Ser-Cys-Val-Phe-Ala-His-Asn-Tyr-Asp-Tyr-Leu-Val-Cys with a K, o f 0.8
pM.
The steps involved in the fabrication o f the sensor surface include the formation o f a self
assembled monolayer (SAM) using a thioctic acid modified ferrocene compound. The use
o f a thioctic acid labelled compound facilitates the chemisorption o f the ferrocene probe
to the electrode surface. The SAM is then diluted using an ethanolic solution o f
hexanethiol. This will help backfill the films and remove physisorbed molecules from the
electrode surface. The sensing probes are then covalently attached to the surface and are
used for subsequent studies with either NS3-4A protease or PSA.

Our studies show that the Hep CV NS3-4A protease can be detected using the biosensor
approach at very low concentrations and this sensor approach is also very specific in the
presence o f high concentrations o f human serum albumin (HSA). The changes in sensor
surface can be directly correlated to the concentration o f the protease.

Studies using this approach with PSA also show similar result.
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CHAPTER 1
INTRODUCTION
Much research has focused on the detection of proteins to help diagnose diseases and
develop drug targets. For example, enzyme such as proteases, integrases and
polymerases are critical for infection. Viral infections for example occur by the
attachment of the envelope glycoprotein to a cell surface receptor, followed by fusion
o f the viral and cellular membranes. Once in the cell, the viral enzymes and structural
proteins form a replication complex that ultimately leads to infection.1 The research
described here focuses on the detection of proteins associated with a disease or
infection. Hepatitis C virus (HCV) and human prostate cancer antigen will be
measured using electrochemical techniques. For this purpose, prostate specific
antigen, a serine protease, a biomarker for prostate cancer, has been selected and the
hepatitis C viral NS3-4A, another serine protease, will be used to study hepatitis C
virus. To better understand these biomarkers, a discussion on serine proteases and
their mechanism of action will be provided in the next section.

1.1.

SERINE PROTEASES
Serine proteases, responsible for proteolysis, are found in different areas of

cellular life and take part in a wide range of physiological processes.2 Proteolysis
represents an important mechanism that participates in numerous biological functions,
including development, apoptosis, homoeostasis, reproduction and host defence.
Approximately 0.6% of human genes are predicted to encode serine proteases, and
this family is even more prevalent in other organisms, notably the anthropods.4 The
nucleophilicity in serine proteases usually depends on a catalytic triad consisting of a

1

serine (Ser), aspartic acid (Asp) and histidine (His) residues5 (Figure 1.1) commonly
referred to as the charge relay system, which was first observed by Blow in 1969.6

Figure 1.1: The Blows charge-relay system in serine proteases. The active site of a
serine protease and the three amino acids Ser, His, and Asp residues required for
proteolysis. The histidine residue is connected to the serine and aspartic acid residue
via hydrogen bonding. Picture re-modified with kind permission from ref. 7

The generally accepted mechanism for hydrolysis of peptide bonds by this class of
proteases is shown in Scheme 1.1.

r^ oh

Scheme 1.1: Reaction scheme depicting the mechanism of hydrolysis by serine
proteases. The reaction shows the attack by the nucleophilic hydroxyl side chain of the
serine residue leading to the formation of the acyl intermediate which is then
hydrolyzed to the free enzyme and the carboxyl function.

The first step of the reaction is a nucleophilic attack by the catalytic Ser residue on the
carbonyl carbon atom of the residue labelled Ri in Scheme 1.1, generating a covalent
2

acyl-enzyme intermediate and a new peptide amino terminus on the Ri residue. A
second nucleophilic attack by a water molecule leads to hydrolysis of the acylenzyme, releasing the new carboxyl group and restoring the catalytic Ser residue to its
initial state.
In addition to the Ser residue, the mechanism, of most but not all, serine proteases
depend on the side chains of a His and Asp residue. The initial mechanism described
in Scheme 1.1 is not explicit about the participation of the Asp and His residues in the
catalytic process. The His side chain serves as a base for activating the nucleophilic
species, e.g the serine residue, and also as an acid that transfers a proton to the leaving
group later in the reaction. The Asp side chain is generally believed to stabilize the
charge on the protonated His residue. The second mechanism is shown in Scheme 1.2

3

Substrate

Substrate

Scheme 1.2: The mechanism of hydrolysis by serine proteases. First the histidine
residue serves as a proton acceptor making the serine residue more nucleophilic. The
proton is then transferred to the leaving group before the nucleophilic attack by a
water molecule. This mechanism is significantly more detailed and highlights the
involvement of this Asp in proton abstraction from Ser 195, followed by nucleophilic
attack on the amide carbonyl. Back proton transfer to the tetrahedral intermediate
from the His converts the amine to the ammonium leaving group, ultimately leading
C-N bond cleavage. Water addition then leads to its decomposition, restoring the
active site.

4

1.2.

HEPATITIS C VIRUS

Approximately 170 million people are chronically affected with the hepatitis C
virus (HCV) worldwide, making HCV a viral pandemic.9 HCV is usually referred to
as the ‘silent killer’ because patients show few or no signs o f infection.10 The Hep C
virus is responsible for chronic liver disease which invariably leads to cirrhosis and
end stage liver disease in humans. Chronic infection with HCV has been reported to
induce insulin resistance thereby leading to steatosis, development o f fibrosis and
resistance to antiviral drugs."
The hepatitis C virus is a 9.6 kb positive-sense, single stranded RNA virus of the
Flaviviridae family12 closely related to the human hepatitis G, yellow fever and
dengue viruses.13 The HCV genome encodes a single polyprotein of 3000 amino acids
(Figure 1.2).14 The HCV viral polyprotein is composed of structural proteins and the
non-structural proteins. The structural proteins are the core (C), envelope proteins 1
and 2 (El, E2) and a small hydrophobic peptide P7. The non-structural proteins,
responsible for disease development, are the NS2, NS3, NS4A, NS4B, NSSA, and
NS5B proteins. The structural proteins are proteolytically processed by host signal
peptidases while two virally encoded proteases from the NS2 and NS3 regions process
the remaining non-structural proteins.15 C, El and E2 are the main constituents of the
viral particle. P7 and NS2 are useful in viral assembly but are not required for viral
replication.16,17 HCV also encodes virus-specific helicases protease (NS3) and
polymerase (NS5B) which are attractive targets for antiviral therapy because of their
importance in its life cycle.

1o
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Figure 1.2: The HCV polyprotein genome showing the four structural and six non
structural proteins. Figure re-modified with permission from ref. 19
Very little is known about the function of the NS4B but it has been proposed to be
responsible for the formation o f the membranous webs in HCV infected cells which
aid the replication process.20

1.2.1. NS3 AND NS4A PROTEASES
NS3 is a serine protease with 180 amino acid residues. The three amino acids His,,
Asp and Ser form the catalytic triad for this protease with the histidine and aspartic
acid located at the N-terminal and the Ser at the C-terminal as indicated in Figure
1.1.21 HCV NS3 protease is considered a bi-functional enzyme. Its N-terminal domain
contains a chymotrypsin-like serine protease required for proteolytic processing and
the C-terminal has a helicase activity.22,23
NS4A is a 54 amino acid residue amphipathic peptide with a hydrophobic N-terminus
and a hydrophilic C terminus which has been reported to be responsible, in
conjunction with the C-terminal of the NS3 protease, for the cleavage of the HCV
i:
polyprotein non-structural junctions.24 It acts as a cofactor for the NS3 protease and
also in the membrane localization of the NS3 and other viral replicase components.
6

25,26,27

x -ray structure of the NS3-4A protease complex28 bound to a macrocyclic

inhibitor (1) is shown in Figure 1.3

Figure 1.3: X-ray structure of the HCV NS3-4A protease complex bound to a
phenylalanine-based macrocyclic inhibitor. The hydroxyl group of the active site
serine residue is involved in a covalent bond with the ketone carbonyl of the inhibitor
while the macrocyclic region o f the inhibitor encircles the methyl group of alanine
156. Reprinted with permission from ref. 28

1.2.2. INHIBITORS OF HCV NS3-4A PROTEASE
The involvement o f the NS3 protease in the development of Hep C infection has
made it an attractive target for antiviral therapy. Much effort is focused on the ability
to detect HCV at an early stage and several attempts have been made by scientists to
develop compounds that exhibit some degree of potency towards the viral proteases.
Some of these compounds have peptide origin while some are non-peptidic. A brief
account of some of the inhibitors that have been synthesized as inhibitors of the HCV
NS3-4A protease complex is provided below.
Several peptide inhibitors of HCV have been synthesized and studies have shown that
the cleavage products at the N-terminal are good inhibitors of the protease. In a 1998
study,

the protease was found to interact with the cleavage products and the enzyme7

product complex was also found to be stable. The NS3 enzyme binds the cleavage
product at the C-terminal rather than the N-terminal showing that the C-terminal of
the inhibitor must be free for binding to occur. Some of the residues suggested for
inhibition studies include: an acidic group, Ser or Ala, Thr and Cys. A good example
is the hexapeptide inhibitor (2) with an IC50 value of 7.5 pM. 30

2

Two oligo-phenols (3 and 4) were isolated from plant extracts of Stylogne
cauliflora sp and were found to exhibit activity towards the NS3-4A complex with
IC50 values of 0.3 and 0.8 pM, respectively.31

Ketoamides,32’3j shown in Scheme 1.3, are another class of inhibitors that have been
used against HCV protease. A tetrapeptide bearing a bicycloproline and a ketoamide
8

(5) were synthesized by Yvonne et. al. with inhibition constants in the nanomolar
(nM) range. Modifications o f the bicycloproline gives fluorinated (6), deoxy (7),
dehydro (8), and ortho-methoxymethylether (OMOM) (9) derivatives.

Further

modification of the Val residue of (5) adjacent to the pyrazine N-terminal gave
inhibitors with improved activities.34’35,36 Ethyl pyrrolidine lactam derivatives have
also been used.

-17

Scheme 1.3: Tetrapeptide ketoamide inhibitors of HCV NS3-4A. The scheme shows
the variation of the bicycloproline residue (based on 5)

In another study the ketoamide group in Boceprivir (10) was removed and replaced
with carbamate or urea derivatives and the IC50 values obtained from the inhibition
assays were in the micromolar range.

->o
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Macrocyclic inhibitors, characterized by a hydrocarbon bridge linking the amino acid
side chain of the tetra peptide, have also been synthesized and have shown potency
against HCV protease with inhibition constants in the nanomolar range.

->Q

Marco et.

a/.40,41 synthesized macrocyclic inhibitors with hydrocarbon bridges between the
second and fourth amino acids with good inhibition constants. Some boronic acid
derivatives,42’43’44 having cyclobutyl45 and aldehydes46 as C-terminal substituents,
were also tested against HCV protease having micromolar inhibition constant values.
An isoindoline moiety was also found to increase the binding affinity of the inhibitors
with one enantiomer being more potent than the other. Li and colleagues synthesized
acylsulfamoyl benzoxaboroles (11) which have also shown potency towards the
protease with ICso values ranging from 0.3 to 0.8 nM47 while Pemi and co worker48
synthesized proline derivatives (12).
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Some aza-bicycloheptane carboxylic acids have also been used as inhibitors with
inhibition constants in the low micromolar range.49 Other inhibitors that have shown
activity against the protease include compounds containing benzimidazole,50 and
benzoxaborole.51 Han et al.52 also synthesized some glycine a-ketoamides (13). Cterminal modifications resulted in inhibitors with good activity against the protease.

13
R= C 0 2H (IC50 = 0.23 |iM) or carboxylic acid isosteres

The TV-phenylsulfonylglycinamides (14) with m-chloro, nitro and phenyl derivatives
were found to have more potency than simple sulfonic acid derivatives with binding
constants in the micro-molar range.

oy

o

IC50 = 8.9 pM
14
Current detection methods for HCV are discussed in the next section.
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1.2.3. CURRENT DETECTION METHODS FOR THE HEPATITIS C
VIRUS
Liver biopsy is a procedure in which a small piece of the liver is removed and
examined for damage. The method used for estimating the nature and severity of liver
damage is usually liver biopsy.

In addition, it is useful in monitoring the efficacy of

various treatments. A biopsy is usually not necessary for individuals who show an
abnormal liver function test but when the liver problem is difficult to diagnose from
the blood or imaging techniques such as x-ray and ultrasound, liver biopsy becomes
necessary. There are currently several methods available for obtaining liver tissue (all
o f which differ in the way the needle is inserted and the risks involved). They are:
percutaneous biopsy, trans-jugular biopsy, laparoscopic biopsy, or fine needle
aspiration guided by ultrasonography or computed tomography (CT) . 54 Aside from
liver biopsy, immunoassay methods based on the amplification of genetic material
have also been used.
To detect HCV, immunoassay and ribonucleic acid (RNA) test are commonly used.
These screening methods employ its antibodies using enzyme immunoassay. This
analysis can be carried out using serum or plasma samples. Examples of immunoassay
and RNA test methods that have been reported include enzyme-linked immunoassay
(ELISA), Western blotting and polymerase chain reaction.55
fmmunoassay techniques have been used in the detection of HCV proteins. In the
work carried out by Lin et al, the HCV NS3-4A and PI antigens were coated on an
immunoassay binding plates. The plates were then washed with the ortho coat buffer
which contains bovine serum albumin and 3% sucrose. Serum samples were then
added to the coated plates and the plates were incubated at 37°C for 1 hour before
12

washing with the substrate solution containing o-phenylenediamine. The plates were
then read at 492 nm relative to the control signal at 690 nm.56 By combining these two
antigens, Lin and his colleagues were able to detect HCV antibodies earlier than the
enzyme-linked immunosorbent assay test systems. In another study, antibodies to the
HCV core and NS4B protease were detected in serum samples.57 Njouom and co
workers synthesized core and NS4B specific peptides. These peptides were then
incubated with serum samples and the antibodies were detected using a commercial
enzyme immunoassay (AxSYM® HCV version 3, Abbott Laboratories Rungis,
France).56 Ross et al, has also used an immunoassay technique in the detection of
•

•

antigens to the HCV core proteins in serum.

CO

In another study by Liu et al, an electrochemical method was used to detect HCV by
exploiting the interaction of BamHI endonuclease with specific DNA base sequences.
In this study, the probe DNA, pre-labelled with thionine, was self assembled on a gold
electrode surface. An oligonucleotide related to the HCV was then hybridized with the
probe DNA. The change in the thionine signal before and after digestion with BamHI
was correlated with the concentration of the HCV DNA hybrid. A liiiear relationship
was observed between the peak current change in the voltammogram and the
concentration of the HCV oligonucleotide in the range 0.1 to 2.5 pM, close to the
normal concentration of HCV RNA of 1.5 to 2.0 in serum and plasma (Scheme 1.4).
The detection limit for this assay was 20 nM.59
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Scheme 1.4: Representation o f a thionine labelled DNA sensor for the detection of
HCV. The gold electrode is first modified with a thionine labelled probe which is then
hybridized using an HCV specific oligonucleotide. Upon digestion in BamHl
endonuclease, the hybridized DNA is cleaved at a specific position (between two
guanine bases) which results in the reduction or absence of the signal from the
thionine. Reprinted with permission from ref. 59

Although immunoassay techniques are specific methods of determining proteins, their
major disadvantage lies in the fact that sometimes active and inactive forms of the
protein cannot be distinguished and partial degradation of the protein may result in the
elimination or alteration of the interaction of the antibody with the protein.60 Some of
the assay methods currently used for HCV and their detection limits are given in Table
1.1.
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Table 1.1: Assay methods for HCV detection and their detection limits
Manufacturer
Abbott Laboratories
Ortho-Clinical
diagnostics
Roche

Lowest detection
limit
Core antibodies 0.09 pg/mL
Core antibodies 1.5 pgmL’1
HCV detected

Assay
AxSYM
ORTHO®

COBAS® Amplicor RNA
RNA

Electrochemistry

0.007 pg/mL
20 nM

Now that we have evaluated the HCV protease, its inhibitors and methods of
detection, the discussion will shift to the next target in this research work.
1.3.

PROSTATE CANCER AND PROSTATE SPECIFIC ANTIGEN

Prostate cancer is one of the most common causes of death in men in the Western
world.61 A biomarker for prostate cancer is prostate specific antigen (PSA). PSA is a 34
kDa glycoprotein which is found in the epithelial cells of the prostate. PSA is a serine
protease similar to the glandular Kallikrein family of proteases and it is one of the three
abundant prostatic secreted proteinases in human semen62. The crystal structure of a
PSA analogue5 is shown Figure 1.4. Please note the presence of the Asp, His and Ser
residues in this serine protease in the active site. The mechanism of proteolysis is as
described earlier in Scheme 1.2
Prior to the use o f PSA as a prostate cancer marker, prostatic acid phosphatase (PAP)
was used. PAP was later replaced by PSA because of the low tissue specificity of
PAP.63,64 PSA was isolated in the late 70s and further studies showed a correlation
between PSA levels and prostate cancer.65
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Figure 1.4: Left: Crystal structure of prostate specific antigen (PSA) showing the three
amino acid residues, Asp-102, His-57 and Ser-195 of the catalytic site. Right: structure
o f the active site with bound Zn or Hg. Reprinted with permission from ref. 5
Several pathways have been proposed by which PSA carries out its regulatory activity,
including zymogen activation, allosteric regulation, proteolytic internal cleavage and
proteinase inhibition. For example, for zymogen activation, the PSA protease undergoes
a conformational change. In PSA this process results in its conversion from the inactive
to the active form. This conformational change may be autocatalytic or it may require an
enzyme molecule, or can be a non-enzymatic process. PSA then loses its activity by
conversion from the active form to the inactive form through internal cleavage and the
protease interacts with proteinase inhibitors.66 The primary structure of PSA was first
determined in 1986 in a study that showed that PSA contains 240 amino acid residues.67
Subsequent studies however, reported 237 amino acid residues.68,69 After the amino
sequence determination of PSA some inhibitors were synthesized, some of which are
described in the next section.
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1.3.1. IN H IB IT O R S O F P R O S T A T E S P E C IF IC A N TIG E N

Peptide and non-peptide inhibitors have been synthesized for PSA.70 71 The design
of peptide inhibitors for PSA started with the work by Watts in 1986 after the amino
acid sequence of PSA was determined.64 Watts and colleagues then tried to monitor the
activity of PSA in the presence of a chymotrypsin-like substrate yielding a specific
activity o f 9.21 pM min"' mg'1 and Km and kcat values of 15.3 mM and 0.075 s' 1
respectively. The efficacy of three peptides, HK2p01 (15) and two others, was tested
against PSA and a series o f addition and deletion experiments to find out the effect of
different residues on the inhibition of PSA showed that replacing Arg, Phe, Lys, Val,
and Trp residues with Ala greatly reduced the activity o f the peptide.72

Short peptides containing 12 amino acids, isolated from a phage, were used as
inhibitors o f PSA by Aggarwal et a lP Peptide (16) was found to increase in activity
upon dimerization.
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Another short peptide containing 19 amino acids (17) was identified from phage as an
inhibitor o f PSA. This peptide reported by Wu et al was shown to bind specifically to
PSA and no other serine protease. 74

Peptide aldehydes (18) and boronic acid derivatives (19)75’76 have also been
synthesized. Studies showed that there was a preference for hydrophobic and
hydrophilic residues in some positions giving rise to inhibition constants in the micro
to nanomolar range.

77
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Ki = 37 nM

Kj = 65 nM

1.3.2. CURRENT DETECTION METHODS FOR PROSTATE CANCER
Detecting prostate cancer at an early stage increases the success of treatment and
survival. Currently PSA is a biomarker for early detection of prostate cancer. PSA is
also an ideal marker for the identification of recurrent disease after treatment. Among
men undergoing radical prostatectomy, the persistence of undetectable or increased
serum levels can be used to confirm the absence or recurrence of disease.78,63 The
prostate can be examined directly by either digital rectal examination (DRE) or the
transrectal ultrasound (TRUS). Both methods permit some estimate of the prostate
size as an indication o f urinary obstruction and detection of suspicious nodules that
warrant further evaluation for cancer. Although DRE has the advantage of low cost,
requires only an examining glove and a few seconds of time, it is limited by the skill
19

of the examiner and low positive predictive value as screening tests for prostate
cancer. Transrectal ultrasonography on the other hand, requires ultrasonography
equipment, introduction of the transducer into the rectum, and a trained interpreter.
Both methods are unpleasant for the patient and the physician.79 PSA levels of 4 ng/ml
(100 pM) are considered normal and elevated levels of PSA in the blood and/or an
abnormality during physical examination indicate the presence of prostate cancer.

In

1989, Catalona and colleagues demonstrated that serum PSA measurements are useful
for prostate cancer detection.81 Some of the ways in which serum PSA is used
clinically to detect prostate cancer include age-adjusted PSA, analyses of PSA
isoforms (free and bound/complex PSA), PSA kinetics (doubling time and velocity),
as well as PSA density in improving the specificity of PSA.82 The one step PSA test is
a colloidal gold enhanced immunoassay for the determination of PSA in human
serum, plasma and whole blood. The nitrocellulose membrane was treated with mouse
anti-human PSA McAb in the test region. During the assay, the serum, plasma and
whole blood specimen is allowed to react with the coloured conjugate (antibodycolloidal

gold

conjugate);

the

mixture

then

migrates

on

the

membrane

chromatographically by capillary action. If PSA is present in the specimen, the
specific antibody-PSA-colored conjugate complex will form in test region on the
membrane. Absence o f this coloured band in the test region suggests a negative result.
This approach was used by Lin et al in 2008 in the detection of PSA with a detection
level of 0.02 ngmL' 1 (Figure 1.5). The immunochromatographic biosensor in this
study integrates the test strip with an electrochemical detector.83
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labeled Ab

Figure 1.5: Representation of the immunochromatographic
biosensor. Reprinted with permission from ref. 83

electrochemical

Immunoassay has been used as a detection method for PSA. Recently, mass sensing
biosensors were used in the detection of PSA.84 In this study, a silicon wafer was
functionalized with a triethoxysilylbutyraldehyde. The aldehydes group was then
reacted with the amino groups in the antibody. The antibody modified surface was
reduced using sodium borohydride (NaBH4). The reduced surfaces were then used for
sensing PSA in serum samples with a detection limit o f 4 ng mL' 1(Figure 1.6)
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Figure 1.6: Illustration o f the BioCD sensor surface. A silicon wafer is functionalized
with a terminal aldehydes group which is then used for the covalent attachment of the
antibody to the electrode surface. The antibody modified surface is then used in the
detection of PSA. Reprinted with permission from ref. 84
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PSA has also been detected with the use of electrochemical techniques. Roberts et
al, detected PSA by exploiting its proteolytic ability. A nanowire electrode was
modified with a peptide containing a sequence that is recognized and cleaved by PSA.
This sequence was embedded in the middle of an anionic and a cationic sequence. The
peptide was immobilized on the electrode surface by Au-S linkage (Scheme 1.5).
Upon cleavage of the peptide, the electrocatalytic current signal from the solution
or

based redox probes was used as a measure of concentration.

Using the gold

nanowire, PSA was detected between the concentration range 1pM to 100 pM.

CEEEEHSSLKQKKK
anionic
domain

s

cleavage cationic
sequence domain

Scheme 1.5: Representation of the electrocatalytic detection of PSA. The gold
nanowire was first modified with a cysteine-containing peptide sequence. The peptide
sequence is then cleaved at a specific site by PSA. The electrocatalytic current signal
is then used to monitor the cleavage of the peptide. Reprinted with permission from
ref. 85

In another report, the nano-wire electrodes were functionalized with aldehyde groups
which facilitated the covalent attachment of the PSA antibody.

oz:

The sensor surface is

then exposed to PSA and detection was carried out using a biotin labelled secondary
22

antibody. This secondary antibody is then detected by introducing an alkaline
phosphatase complex which converts 2-phospho-L-ascorbic acid to L-acsorbic acid.
The self oxidation of the ascorbic acid causes a reduction of Ag+, from AgNCfy to
silver which is deposited on the electrode surface. The Ag deposits were stripped and
measured by square wave voltammetry. PSA detection using this approach was
achieved within the concentration range 3- 50 ngmL'1.

Scheme 1.6: Representation of a PSA immunosensor. The glutaraldehyde
functionalized gold nano-wire was covalently attached to the PSA antibody which is
then incubated with PSA. The interaction of the secondary antibody with PSA is
measured by quantifying the electrodeposition of Ag at the gold electrode. Reprinted
with permission from ref. 86

Zhao and coworkers used a labelled electrochemical technique in the detection of
PSA.

In their report, the proteolytic activity of PSA similar to the work done by

Roberts et. al. was used as a measure of concentration. A gold electrode was modified
with a ferrocene functionalized peptide sequence; the electrode surface was then
backfilled to remove physisorbed materials before incubation in PSA solution (Figure
1.7). A plot of peak current decrease against concentration was found to be linear in
range 0.5 - 40 ng m f 1with a detection limit o f 0.2 ng m L 1(6 pM).
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Figure 1.7: Illustration of the ferrocene functionalized detection o f PSA. The
electrode surface is functionalized with a PSA cleavage sequence via a Au-S linkage.
The electrode surface is then backfilled before incubation in PSA. After incubation
in+- the PSA solution, a signal reduction is observed due to the loss of ferrocene from
the electrode surface. Reprinted with permission from ref. 87

Some of the assay methods for PSA and detection limits are given in Table 1.2.
Table 1.2: Assay methods for PSA detection and their detection limits
Manufacturer

PSA isoforms detected

Abbott Diagnostics AxSYM

Free PSA
Total PSA
Total PSA
Free PSA
Total PSA
PSA antibody
Free PSA

Abbott Diagnostics IMx
Roche Elecsys
BioCD
Electrochemistry

1.4.

Lowest detection
limit (ng mL'1)
< 0.02
<0.04
<0.04
<0.01
< 0.002
4
0.2

BIOSENSING

A biosensor is an analytical device, which incorporates a biological recognition
element in close proximity or integrated with a signal transducer to provide a sensing
system specific for the target analyte. Biosensors have received a lot of attention
24

because they play a significant role in the monitoring of a wide range of diseases and
pathogens. For example, the development of the electrochemical-based glucose
biosensor for diabetes has made life much easier for many patients in the diagnosis
and management of a worldwide health problem.88

Many different types of

biosensors are presently available. However, they all basically comprise of a
biological recognition element or bio-receptor, which interacts with the analyte and
responds in some manner that can be detected by a transducer as shown in Figure 1.8
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cell cu ltu re

human samples
blood« u rin e

¿ I
"
Food samples

rfzTFi

{i*

V

V

^

*

I

PET derices

nucleic
acids
nu<

signal
am plifier

;
n a n o tn re array

'

cells

signal
processor

a*

y

i

n anoparticle

antibodies

<

\

¡:

electro des

enzym es
U n r« n ii:a t*) t u f l u

irater,soil
Sam ples

bioreceptor

electrical interface(s)
Transducers

display
E lectronic system

Figure 1.8: Shows the three components of a biosensor. The three components being
the bioreceptor, electrical interface both of which constitute the transducer and the
electronic system. Image reprinted from ref. 89

Electrochemical biosensors are ideally suited for non-hospital environments due to
their high sensitivity, portable field-based size, rapid response time, ease of operation
•
00
and inexpensive operational capabilities.
In the next sections, the use o f electrochemistry in biosensing will be introduced.
1.5.

FERROCENE IN BIOSENSORS
The discovery o f ferrocene in 195191 has greatly influenced the field of

organometallic chemistry, and since that time ferrocene has been used in many
25

organometallic research studies but most importantly in the area of bio-organometallic
chemistry. The usefulness of ferrocene in electrochemistry is due to the fact that
ferrocene is redox active as shown in Scheme 1.7. The cyclopentadienyl rings can be
modified, to increase specificity and stability under physiological conditions.

Scheme 1.7: Shows the Redox reaction in which ferrocene is converted to
ferrocenium ion by the loss o f an electron.

Ferrocene can be readily modified with a wide range of bio-molecules and these
conjugates have been exploited in biosensor applications.93,94 For example, Plumb et
al 93 synthesized some ferrocenoyl tetra peptides (20) and the inhibition of papain
using these peptides was monitored in solution.

The inhibition constant was determined to be 9 pM at pH 6.2 and this report paved
way for the work done in 2007 by Mahmoud et al 96 who reported the use of surface
active ferrocene conjugates in the detection of papain as shown in Scheme 1.8.
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Scheme 1.8: Schematic diagram of a ferrocenoyl sensor surface with a covalently
attached peptide before and after interaction with papain. Adapted and redrawn from
ref. 96

The ferrocene peptide conjugate (21) was linked to thioctic acid on the other
cyclopentadienyl ring which facilitated the immobilization of the conjugates to the
gold surface. The interaction of the immobilized peptides with papain was then
monitored using cyclic voltammetry.
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The first report on the use of ferrocene conjugates in the detection of HIV
integrase was by Kerman et al.

Q7

This approach was also extended to the detection of

•
Q'X
HIV protease, integrase and reverse transcriptase (Scheme 1.9).
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Scheme 1.9: The steps in the fabrication of a ferrocene biosensor. First the ferrocene
amino acid derivative is immobilized on a gold surface using Au-S bonds. The
pendant carboxylic acid group is then activated on the surface before covalent
attachment of the peptide. The peptide modified surface is then used to monitor
binding interactions with the target. Reprinted with permission from ref. 97

A comparison of the measurements before and after binding indicates that there was a
shift in the redox potential of the ferrocene label after treatment with the viral
enzymes and this was related to the difficulty of oxidizing the ferrocene label. Sato et
al 98 also utilised ferrocene labelled oligonucleotides in their study and they
discovered

that the

current decreased after treating their electrodes with

deoxyribonuclease due to the loss of ferrocene from the electrode surface (Scheme
1.8 ).
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Scheme 1.10: An electrochemical assay of RNase 1. The electrode surface is modified
with a ferrocene oligonucleotide which is cleaved off on interaction with the
deoxyribonuclease 1 (DNase 1). Adapted from ref. 98

Our group has used ferrocene conjugates in the detection of several kinases and
peptides.99,100
1.6.

SURFACE PLASMON RESONANCE

Surface plasmon resonance (SPR) is a method for characterizing macromolecular
interactions. It is an optical technique that uses the evanescent wave phenomenon to
measure changes in refractive index (within -300 nm) near a sensor surface. The
binding o f an analyte in solution to its surface bound ligand results in a change in the
refractive index (Figure 1.9).
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Surface plasmon on the gold layer

Figure 1.9: Schematic representation of the surface plasmon resonance instrument
showing the polarized light passing through a prism at the back of the metal (e.g
gold). The reflected light is then detected and recorded as reflectance intensity.
Adapted and redrawn from ref. 101

SPR has the advantage o f being sensitive to the optical properties of surface layers and
the ease of their real time continuous monitoring. This interaction is monitored in real
time and the amount of bound ligand and rates of association and dissociation can be
measured with high precision. In the past several years, SPR has taken its place as a
mature biophysical technique for the analysis of molecular recognition events. SPR
s
biosensors have become standard instruments in biochemical and biophysical research
centers. SPR has been employed in the detection of proteins.102 103

1.7.

ELLIPSOMETRY

Ellipsometry

is

a

non-destructive,

optical-surface-sensitive

method

for the

investigation of protein adsorption mainly at metal surfaces. The technique is based on
measuring the change o f the state polarization o f elliptically polarized light when it is
reflected at a surface. From the changes in the ellipsometric angles (A, X
P, see Figure
1.10, and the refractive index, the thickness of the film can be deduced
30

Figure 1.10: A schematic diagram of analysis using an ellipsometer. The polarisation
of the incident light is changed upon reflection from the surface. The angle C is
measured with respect to the angle of incidence. P0 and A0 are the analyser and
polarizer angles, with A0 ranging between 0 and 90°. Reprinted with permission from
ref. 104

Ellipsometry has been utilized in several studies including adsorption105,106 and
desorption of proteins.107

1.8.

OBJECTIVE

s

The main objective of this research is to develop a method by which biomarkers of
hepatitis C infection and prostate cancer can be detected using protein-peptide
interactions. Currently the methods available for the detection of HCV and prostate
cancer are only useful when the disease condition is at an advanced stage. Thus, there
is a need to develop methods which can detect these diseases at an early stage and at
very low concentrations. Our approach is to take advantage of the protein-peptide
interaction in the design of our biosensor using ferrocene as a redox probe. Peptides
which have been known to inhibit the proteins o f interest will be utilized in this
research work. Specifically, it is planned to target NS3-4A protease and prostate
31

specific antigen. The inhibitory peptides utilized in this work were reported to have
activity against the selected biomarkers with good binding constant. 30,74
Asp-Glu-Ile-Val-Pro-Nva is the inhibitory peptide for the NS3-4A with an IC50 of 7.5
pM
Ser-Lys-Ser-Lys-Ser-Lys-Ser-Cys-V al-Phe-Ala-His-Asn-Tyr-Asp-Tyr-Leu-Val-Cys
is the inhibitory peptide for PSA and it possesses a Ki of 0.8 pM.

\
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CHAPTER 2
ELECTROCHEMICAL DETECTION OF HEPATITIS C VIRAL NS3-4A
PROTEASE

2. Introduction
With the current statistics of Hepatitis C virus (HCV) infection hitting the millions9
and the infected individuals unaware of infection10 there is a need to develop a method
by which HCV can be detected clinically and at an early stage. Detection at an early
stage will not only improve diagnosis, it will also increase the chances o f survival due
to early treatment. The Hep C virus is responsible for chronic liver disease which
invariably leads to cirrhosis and end stage liver disease in humans. Chronic infection
with HCV has been reported to induce insulin resistance thereby leading to steatosis,
development of fibrosis and resistance to antiviral drugs." An attractive target for the
study and early diagnosis of HCV is the NS3-4A protease. The HCV NS3-4A protease
is a non-structural protein located on the genome of HCV and it is responsible for the
cleavage of the polyprotein.1524 The importance of this protease makes it interesting
for study. Currently the available methods for detection for HCV include liver
biopsy52'53, Polymerase chain reaction54'55and immunoassay methods.62 63 Our
approach to the study o f NS3-4A protease is by exploiting peptide-protein interaction
using the thioctic acid (The) modified ferrocene derivative [(Thc)NHFc(CO)OH] (22)
in the study of the target protein. The introduction of thioctic acid will enable the
covalent attachment of the compound to the gold surface through S-Au linkages since
sulfur compounds have a high affinity for gold surfaces (Figure 2.1).
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Figure 2.1: Left: The structure of the thioctic acid modified ferrocene compound.
Right: shows one of the cyclopentadienyl (cp) rings attached to a gold electrode
surface through S-Au linkages leaving the other ring free for further modification

The carboxyl group on the other cp ring provides a handle for the introduction of the
bio-recognition element that will enable the binding of NS3-4A protease. This
interaction can be quantified electrochemically by monitoring the response of the
ferrocene as a function of NS3-4A protease concentration
's
2.1.

Experimental procedure

2.1.1. Materials
The working gold electrodes, 99.99% polycrystalline, 2 mm diameter, were purchased
from CH instruments Inc. (Texas USA). HCV NS3-4A protease purchased from
Anaspec (Freemont CA) and the HCV NS3-4A protease specific peptide purchased
from Celtek Bioscience (Tennessee USA) were used as received. Ethanol used
throughout this work was freshly distilled prior to use. Deionized water (18.2 MQ cm
resistivity) from a Millipore Milli-Q system was used throughout this work. All other
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reagents were analytical grade, ellipsometry measurements were recorded at the
Nanofabrication Facility of the University of Western Ontario using the Variable
Angle Spectroscopic Ellipsometer (VASE ) made by J.A. Woollam Co. (Lincoln,
USA) and SPR measurements were recorded on a GWC SPR imager II (GWC Inc.
Madison, USA). SPR analysis was carried out using spot ready SPR chips purchased
from GWC Inc. The pH measurements were recorded on a Fisher basic accumet AB
15 pH meter (Fisher Scientific Canada). CH2CI2 (BDH, ACS grade) used for synthesis
was dried by CaH2- All other solvents used for synthesis were used as received. !H
NMR spectra were recorded on a Varian Mercury 400 MHz spectrometer with a 'H
frequency of 400 MHz.
2.1.2, Synthesis
Ferrocene derivative, (Boc)NHFcCOOMe (23), (Thc)NHFcCOOMe (24) and
(Thc)NHFcCOOH

(22)

were

prepared

using

standard

peptide

coupling

procedures.108,109

Synthesis of (Thc)NHFcCOOMe (24)
(Boc)NHFcCOOMe (23) (0.25 g, 0.70 mmol) was dissolved in dried CH2C12 (5 mL)
at 0°C. TFA (5 mL) was then added dropwise under nitrogen, the ice bath was
removed and the reaction mixture was stirred for 45 minutes. Excess CH2CI2 was then
added to the mixture and the TFA was neutralized with TEA. Thioctic acid (0.14 g,
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0.70 mmol) activated with HOBt (0.13 g, 0.84 mmol) and HBTU (0.32 g, 0.84 mmol)
in dry CH2CI2 at 0°C for 2 hours was then added to the deprotected ferrocene solution.
The resulting mixture was stirred overnight at room temperature and then washed with
saturated NaHCCh followed by citric acid solution and saturated NaCl solution. The
product was dried with Na2SC>4 before purification by column chromatography using
CHCI3: EtOAc (8:2). The product was a yellow solid with a yield of 51%; 'HNMR
(CDCh/ppm): 6.63 (s, 1H, NH), 4.77 (2H, ortho-H o f Fc), 4.58 (2H, ortho-H of Fc),
4.41 (2H, meta-H of Fc), 4.05 (2H, meta-H o f Fc), 3.79 (s, 3H, COOCH3), 3.60 (m,
1H, -S-S-CH), 3.19(m, 2H, -S-S-CH2), 2.5 (m, 1H, -S-CH2-CH2), 2.32 (t, 2H, CH2CONH-), 1.18 (m, -S-CH-CH2-, 2H), 1.35 (m, -CH2-CH2-CH2-CONH-, 2H), 1.52
(m, -CH2-CH2-CH2-CH2-CONH- and -CH2-CH2-CH2-CH2-CONH-, 4H).

Synthesis of (Thc)NHFc(CO)OH (22)
(Thc)NHFcCOOMe (24) (0.10 g, 0.22 mmol ) LiOH (0.016 g, 0.66 mmol.), H20 (1
mL) and THF (5 mL) were stirred at room temperature for 24 hours. The THF was
removed in vacuo and 10 mL of 0.1 M NaOH was added. The aqueous solution was
poured into 1 M HC1 to precipitate the product. 'HNMR (DMSO-d6/ppm): 12.0 (s,
1H, -COOH), 9.23 (s, 1H, NH), 4.61 (4H, ortho-H o f Fc), 4.28 (2H, meta-H of Fc),
3.91 (2H, meta-H of Fc), 3.59 (m, 1H, -S-S-CH), 3.15 (m, 2H, -S-S-CH2), 2.75 (m,
1H, -S-CH2-CH2), 2.15 (t, 2H, -CH2CONH-), 1.52 (m, -CH2-CH2-CH2-CH2-CONHand -CH2-CH2-CH2-CH2-CONH-, 4H) 1.35 (m, -CH2-CH2-CH2-CONH-, 2H), 1.18
(m, -S-CH-CH2-, 2H).

A comparison of the 1HNMR data for the ferrocene conjugate 23 and 24 shows the
disappearance of the Boc protons at 1.5 and the signals corresponding to the aliphatic
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protons in thioctic acid were observed between 3.3 and 1.2 ppm. The amide proton
was also shifted downfield from 5.7 to 6.6 ppm (Figures 2.2).
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Figure 2.2: Partial ‘HNMR of (Thc)NHFcCOOMe (24) and (Boc)NHFcCOOMe (22)
in CDCI3.

The hydrolysis of 24 resulted in the loss of the methoxy proton signal at 3.7 ppm and
the appearance of a new signal at 12.0 ppm in DMSO corresponding to the proton of
the carboxylic group (Figures 2.3).
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Figure 2.3: Partial 'HNMR of (Thc)NHFcCOOH (22) in DMSO-d6 and
(Thc)NHFcCOOMe (24) in CDC13

2.1.3. Electrochemical measurements
All electrochemical studies, including cyclic voltammetry (CV), square wave
voltammetry (SWV), and electrochemical impedance spectroscopy (EIS), were
performed with an electrochemical analyzer (CH Instruments 650c, Texas, USA),
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connected to a personal computer (Figure 2.4). All measurements were carried out at
room temperature in an enclosed and grounded Faraday cage. A conventional three
electrode system was used: the peptide-modified gold electrode as working electrode,
a platinum wire as a counter electrode, and Ag/AgCl reference electrode in 3M KC1.
The reference electrode was always isolated from the cell via a 2% agar salt bridge
(1M KNO3) to avoid the leakage of the chloride ions from the reference electrode to
the measurement system. All electrochemical experiments were started from the open
circuit potential to prevent sudden potential-related changes in the SAM. All CV
experiments were performed at a scan rate of 100 mVs'1. The scanned potential range
was from 200 to 500 mV. SWV experiments were recorded in the same potential
range with a step potential of 4 mV, amplitude o f 25 mV, and a frequency of 25 Hz.
Impedance measurements were recorded at an applied voltage of 250 mV (which is
the formal redox potential of [K3(Fe(CN)6)]/ [K4(Fe(CN)6)] versus Ag/AgCl reference
electrode in Tris-C104 buffer (pH 8.0, 20 mM), a modulation amplitude of 5 mV and a
frequency range of 0.1 Hz to 100 KHz.

Figure 2.4: Left: the three electrode electrochemical setup. The Ag/AgCl in 3M KC1
reference electrode is connected to the buffered solution containing the gold working
electrode and the platinum wire counter electrode through a salt bridge (1M KNO3 in
2% agar). Right: the potentiostat connected to a computer and the grounded Faradaic
cage in which the electrodes are enclosed.
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2.1.4. Surface Plasmon Resonance
The SPR experiment was carried out using gold SPR chips (Figure 2.5) obtained from
GWC technologies. Gold SPR chips were rinsed with milliQ water and then dried
with nitrogen before modification.

Figure 2.5: Image of the SPR spot ready chips

2.1.5. Ellipsometry analysis
Ellipsometry is based on the change of the state polarization of elliptically polarized
light when it is reflected at a surface. These changes in the ellipsometry angles (A, T)
can then be used to evaluate the refractive index and the thickness of the film.
Ellipsometry analysis was used to characterize the sensor surfaces.

2.1.6. Cleaning and surface modification
The sputtering gold surface used for ellipsometry analysis was cleaned first with
Milli-Q water and then with 0.5M H2SO4 for 1 min before washing with water and
sonication in ethanol for 10 min to reduce the formed gold oxide. After drying with
nitrogen, the modified surfaces were prepared as described earlier.
Prior to electrochemical experiments, the polycrystalline gold electrode (2 mm
diameter) was polished with 0.3 and 0.05 pm alumina slurry, cleaned in 0.5 M KOH
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and then washed with copious amount of MilliQ water. The electrode was then
cleaned electrochemically in 0.1M H2SO4 within the potential range of 0-1.45 V vs
Ag/AgCl until a stable gold oxidation peak at 1.1 V was obtained. The electrode was
sonicated in ethanol and dried with nitrogen. The roughness factor of the gold
electrodes was 1.22 ± 0.15. This value was determined by measuring the cathodic
charge required to reduce the oxide layer on the gold surface. The cleaned electrode
surfaces were then incubated in 4 mM ethanolic solution of the thioctic acid modified
ferrocene amino acid derivative for 18 hrs at room temperature. After the 18hrs
incubation period, the electrode surface was characterized by CV in 20 mM Tris-C104
buffer pH 8.0 (Figure 2.6).

Potential (mV)

Figure 2.6: Left: cyclic voltammogram of the thioctic acid modified ferrocene
derivative in 20 mM Tris-C104 buffer, pH 7.8, at different scan rates ranging from 10
to 300 mVs'1. Right: plot of the anodic and cathodic current densities versus scan
rate.

The peak current for the ferrocene redox reaction was found to be proportional to the
scan rate in the range 10 to 300 mVs'1. This behaviour is indicative of a surface
confined redox probe and the formation of a stable layer without diffusion of the
electroactive species to the electrode surface.109
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To prepare the sensor surface, the modified electrode surface was washed with ethanol
and sonicated in ethanol for another 10 mins before backfilling with 1 mM ethanolic
solution of hexanethiol for 5 mins. The blocked electrode surface was then activated
with N-hydroxysuccinimide (NHS,

85 mg, 0.738 mmol) and

l-ethyl-3-(3-

dimethylaminopropyl) carbodiimidehydrochloride (EDC.HCI, 32 mg, 0.167 mmol).
The surface was incubated in a solution of NS3-4A protease specific peptide (50 mM
phosphate buffered solution pH 7.8). The remaining active ester was quenched in
ethanolic 100 mM ethanolamine solution for 10 mins at room temperature. Finally, the
electrode was washed with MilliQ water to give the peptide-modified sensor surfaces
(Figure 2.7).

Figure 2.7: Cyclic voltammograms o f the Hep CV NS3-4A protease biosensor after
immobilization in (a) thioctic acid ferrocene derivative (b) hexanethiol (c) activation
with NHS/EDC and (d) NS3-4A specific peptide, in 20 mM Tris-HCl buffer (pH 8.0)
containing 0.1 mM NaC104. CV was recorded at a scan rate of 100 mVs'1. Reference
electrode is Ag/AgCl (3M KC1) and platinum electrode was used as the counter
electrode

From the background-subtracted CV data (data not shown), the Coulombic charge was
obtained by integration, which allowed the determination of the surface coverage of
the redox-active probe according to the equation T= Q/nFA, where Q is the area of the
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cathodic peak, n is the number of electrons involved in the Fc redox reaction (n = 1), F
is the Faraday’s constant, and A is the area of the electrode. The surface coverage (T)
was calculated as 3.77± 0.9 xlO 11 mol cm'2 after the formation of the SAM. The
surface coverage was estimated to be 1.57 ± 0.3 xlO 11 mol cm'2 after backfilling with
hexanethiol and 1.01 ± 0.04 xlO

mol cm'2 after modification with the NS3-4A

protease specific peptide. These values indicate a high quality packing of the electrode
surface.110
2.2.

Results and Discussion

The approach to the detection of NS3-4A is shown in Figure 2.8. The biosensor
approach is based on the interaction of the peptide inhibitor to the target. The thioctic
acid portion of the molecule facilitated immobilization on the gold surface. With the
ferrocene moiety close to the electrode surface, the interaction with HCV NS3-4A
protease can be monitored by the changes in the electronic response of the ferrocene
before and after modification.95 After the formation o f the self assembled monolayer,
the electrochemical characteristics of the ferrocene modified surfaces were monitored
using cyclic voltammetiy, square wave voltammetry and electrochemical impedance
spectroscopy.
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0.

Scheme 2: Representation of the NS3-4A sensor preparation. The electrode surface is
modified with a thioctic acid ferrocene derivative through Au-S linkages. The
electrode surface is the backfilled with hexanethiol before activation with EDC/NHS.
The peptide is then attached covalently to the electrode surface. The prepared
electrode surface is then used for the detection of NS3-4A.

NS3-4A protease Analysis

The prepared sensor surface was exposed to NS3-4A protease complex for 1 hour.
Upon binding of the HCV NS3-4A protease to the surface-bound protease specific
peptide, a shift to a higher potential together with a decrease in the peak current
density was observed. Table 2.1, indicating that the oxidation of the ferrocene became
difficult.
Table 2.1: Electrochemical properties of the sensor surface before and after HCV
NS3-4A addition. Measurements were made in 20 mM Tris-C104 pH 8.0 buffered
solution with NaC104 as the supporting electrolyte. Values of E°and AE are in mV.
The values in parentheses represent the standard deviations from at least three
electrode measurements
E°
AE
ip
Peptide
320(2)
23(6)
1.02(0.06)

HCV protease

339(1)

35(5)
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1.01(0.02)

Impedance measurements were also recorded for the peptide modified surface before
and after exposure to the NS3-4A complex solution. From the Nyquist plot, a high
capacitive contribution (Zim) was initially observed compared to the resistive
component (Zre). This observation, also observed by Labib et al, was attributed to the
close proximity of the ferrocene moiety to the electrode surface which in turn induces
a decrease in the resistance at the electrode interface shown in Figure 2.8.110

Figure 2.8: Nyquist plot (Z,m vs Zre) o f the peptide modified surface [•] before NS34A addition and [♦ ] after NS3-4A addition and the equivalent circuit used in fitting
the data. Impedance measurements recorded in Tris-C104 (pFl 8) buffered solution at
an applied potential of 250mV, modulation amplitude of 5mV and frequency range
O.lHz-lOO kHz, using Fittings to the equivalent circuit are represented by solid lines.

To overcome the high capacitance problem and also to obtain meaningful results from
the analysis, an external redox probe [Fe(CN)6]47 [Fe(CN)6]3" was introduced giving
rise to an electrocatalytic signal and a reduction in the capacitive contribution.
The concentration dependence response for NS3-4A was measured by SWV and EIS
because the current intensity of the signal was too low and CV measurements did not
have sufficient sensitivity for detection. Several concentrations of HCV NS3-4A
protease, made from serial dilution of a 0.2 pM stock solution, were incubated with
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the NS3-4A specific peptide. The SWV measurements were recorded in the absence
of the [Fe(CN)6]47 [Fe(CN)6]3' external probe. This allowed a comparison of the
response from the ferrocene signal in the absence of the electrocatalytic contribution
from the [Fe(CN)6]47 [Fe(CN)6f

redox probe.110

From the SWV plot, the current density decreased with increase in the concentration
of NS3-4A and a plot o f the change in current density was linear in the range 5-50 pM
(slope = 0.03591 pAcm^pM 1, R2 = 0.9474) as shown in Figure 2.9

Figure 2.9: Left: Square wave voltammogram of the electrode surface after
modification with (a) 5 (b) 10, (c) 25 (d) 50 and (e) 100 pM of HCV NS3-4A and
Right: the plot o f the change in current density against concentration. Error bars
represent standard deviations

Impedance measurements were also recorded for the different concentrations of NS34A protease. To obtain quantifiable results from the impedance measurements, the
impedance data was fitted to an equivalent circuit model shown in Figure 2.10, where
Rs is the solution resistance, Q is the constant phase element, Rct is the resistance to
charge transfer and W is Warburg impedance. The interaction of the sensor surface
with NS3-4A protease was then monitored. The impedance plots, before and after
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modification with NS3-4A, were fitted to the equivalent circuit in Figure 2.10. After
fitting the data, values were obtained from the equivalent circuit (Table 2.2).

Qd
Rs
Ret

W

Figure 2.10: Right: A Nyquist plot showing the addition of different concentrations
of HCV NS3-4A protease after the addition of [►] 5 pM, [★ ] 10 pM, [♦ ] 25 pM,
] 50 pM and [■] 100 pM. The impedance experiments were recorded in a TrisHC1 solution (20mM, pH 8) at an applied potential of 250 mV, modulation amplitude
of 5mV and frequency range 0.1 Hz-100 kHz. Fittings to the equivalent circuit are
represented by solid lines.
A comparison of the Nyquist and Bode plot shows that the overall impedance of the
system increased as the concentration of NS3-4A is increased similar to what is
observed in the Nyquist plot. The solution resistance was also fairly constant in the
Bode plot as shown in Figure 2.11
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Figure 2.11: Bode plot (total impedance versus frequency) for the NS3-4A protease
as the concentration is increased from [►] 5 pM , [•&] 10 pM, [ ° ] 25 pM, [ $•] 50 pM
and [■] 100 pM. The plots were fitted to the same equivalent circuit as the Nyquist
plots.

From the values obtained from the equivalent circuit diagram, Table 2.2, it was
observed that the Rct value increased upon exposure o f the sensor surface to the
protease.
Table 2.2: Equivalent circuit element values for the impedance spectroscopy with Rs
and Rct in Ohmcm2, Q in pSecncm'2 and W in mSsec5cm'2
The values in parentheses represent the standard deviations from at least three
electrode measurements
W
N
Rct
Rs
Q
Peptide

8(2)

61 (3)

0.76(0.2)

124(18)

10(6)

5 pM
10 pM
25 pM
50 pM
100 pM

9(6)
9(2)
9(1)
9(2)
9(2)

37(3)
29(1)
27(5)
28(4)
26(4)

0.81(0.1)
0.84(0.04)
0.87(0.01)
0.89(0.02)
0.91(0.02)

157(3)
160(10)
215(15)
312(7)
609(33)

11(8)
11(1)
9(1)
10(1)
12(2)
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This is also accompanied by a reduction in the capacitance of the system. This is due
to the fact that the protease is now covering more of the surface and as the distance
from the surface increases, the capacitance should decrease. With increase in the
concentration of the protease, the capacitance drops and the resistance increases. The
charge transfer resistance, Ret, versus protease concentration was found to be linear in
the range from 10 to 50 pM (slope = 3.808 il-cm2pM I, R2 = 0.9998) with a detection
limit of 14.8 pM, estimated from 3(Sb/m), where Sb is the standard deviation of the
measurement signal for the blank and m is the slope of the analytical curve in the
linear region Figure 2.12.

Figure 2.12: Plot of the charge transfer resistance of the sensor surface after
modification with HCV NS3-4A protease as a function of concentration. Error bars
represent standard deviations.

As a proof of concept, the surfaces were also characterised by SPR and ellipsometry.
The refractive index of the protein was described by the Cauchy dispersion formula
(n= A + B/A2 + C/ A4 with the parameters A= 1.45, B= 0.01 and C= 0. Ellipsometry
analysis showed an increase in the ellipsometry angle which corresponds to the
adsorption of material to the gold surface.111
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Figure 2.13: Characteristic ellipsometric scan from the gold surface after
modification with compound 20, NS3-4A specific peptide and NS3-4A (lOOpM)

The SPR chip was modified with the PSA specific peptide as described in section
3.1.7. The modified chips were then mounted on the SPR imager and the assay buffer
was first flowed into the instrument. After attaining a steady signal, NS3-4A was then
flowed into the system and the change in pixel intensity was monitored with time. The
change in pixel intensity was converted to % change in reflectivity which was
#
•
• 11' ?
subsequently converted to thickness values using the Jung assumption.

50

1.0-1

Figure 2.14: SPR characteristic signal from the sensor surface after modification
with NS3-4A (lOOpM).

The thickness for the HCV NS3-4A protease was calculated to be 123 ± 13 nm. This
value signifies the formation of multilayer when compared to the value of 224 ± 2.27
A obtained from the ellipsometry measurements.
To test the specificity o f this approach, electrodes were prepared and these electrodes
were incubated in human serum albumin (75 pM), human serum albumin (75 pM )
spiked with 100 pM HCV NS3-4A protease, human serum albumin (1.5 mM) spiked
with lOOpM HCV NS3-4A protease and a solution o f HCV NS3-4A protease (100
pM). The results shown in Figure 3.4, indicates that our biosensor has a high
specificity for the HCV NS3-4A protease.
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Figure 2.15: Square wave voltammogram of the electrode surface after modification
with (a) HSA (75 jiM) (b) HSA (1.5 mM) + HCV NS3-4A (100 pM) (c) HCV NS34A (100 pM) and (d) HSA (75 pM) + HCV NS3-4A (100 pM)

Conclusions
We hereby present a different electrochemical method for the detection of HCV NS34A protease using a protease specific inhibitory peptide. The developed sensor can
detect HCV NS3-4A protease in the range 10 pM to 50 pM with a lower detection
limit of 5pM. This assay method is quite comparable to the 20 nM detection limit
using RNA by Liu et al. 58 The sensor was also able to specifically detect HCV NS34A protease in the presence of 75 pM and 1.5 mM solution of human serum albumin.
We are currently looking at developing a device in which we can incorporate this
sensor approach and ultimately detect HCV NS3-4A clinically. This work shows
promise and it also signifies that this sensor approach can be applied to the detection
o f other proteases for clinical application.
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CHAPTER 3

ELECTROCHEMICAL DETECTION OF PROSTATE SPECIFIC
ANTIGEN
3.0.

Introduction

Prostate-specific antigen (PSA) is a member of the Kallikrein family of serine
proteases.

The expression of PSA is highly restricted to normal and malignant

prostate epithelial cells in men, and for this reason, PSA is used extensively as a
biomarker to screen for prostate cancer"3. Currently detection methods for PSA rely
on immunoassay technique114 and the proteolytic activity of PSA.85"87 Our approach
involves the utility of peptide-protein interaction using a thioctic acid (The) modified
ferrocene [(Thc)NHFc(CO)OH] (20) in studying the target protein. The introduction
of thioctic acid will enable us to covalently attach the compound to our gold surface
through Au-S linkages, since sulphur compounds have a high affinity for gold
surfaces (see Figure 2.1). The carboxyl group on the other cp ring provides a handle
for the introduction of the bio-recognition element that will enable the binding of
PSA. This interaction can be quantified electrochemically by monitoring the response
of the ferrocene as a function of PSA concentration.
3.1.

General experimental procedure

3.1.1. Materials
Prostate specific antigen (PSA), human serum albumin purchased from Sigma Aldrich
Canada and PSA specific inhibitory peptide (PI) purchased from Biobasics
(Markham, Canada) were used as received Potassium ferricyanide was purchased
from Aldrich Canada and potassium ferrocyanide was purchased from EM science.
The working gold electrodes, 99.99% (w/w) polycrystalline with a 2 mm diameter,
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were purchased from CH Instruments Inc. (Texas, USA). All other reagents were of
analytical grade. Ethanol used throughout the work was freshly distilled prior to use.
Deionized water (18.2 MDcm) from a Millipore Milli-Q system was used throughout
this work. Ellipsometry measurements were recorded at the Nanofabrication Facility
of the University of Western Ontario using the Variable Angle Spectroscopic
Ellipsometer (VASE®) made by J.A. Woollam Co. (Lincoln, USA) and SPR
measurements were recorded on a GWC SPR imager II (GWC Inc. Madison, USA).
SPR gold chips were purchased from GWC Inc. The pH of solutions was measured
using the Fisher basic accumet AB 15 pH meter (Fisher Scientific Canada).
3.1.2. Electrochemical measurements
All electrochemical studies, including cyclic voltammetry (CV), square wave
voltammetry (SWV), and electrochemical impedance spectroscopy (EIS), were
performed with an electrochemical analyzer (CH Instruments 650c, Texas, USA),
connected to a personal computer. All measurements were carried out at room
temperature in an enclosed and grounded Faraday cage. A conventional three
electrode system was used (see Figure 2.4): the peptide-modified gold electrode as
working electrode, a platinum wire as a counter electrode, and Ag/AgCl reference
electrode in 3M KC1. The reference electrode was always isolated from the cell via a
2% agar salt bridge (1M KNO3) to avoid the leakage of the chloride ions from the
reference electrode to the measurement system. All electrochemical experiments were
started from the open circuit potential to prevent sudden potential-related changes in
the SAM. All CV experiments were performed at a scan rate of 100 mVs'1. The
scanned potential range was from 200 to 500 mV. SWV experiments were recorded
in the same potential range with a step potential of 4 mV, amplitude of 25 mV, and a
frequency of 25 Hz. Impedance measurements were recorded at an applied voltage of
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250 mV in Tris-C104 buffer (pH 8.0, 20 mM), a modulation amplitude of 5 mV and a
frequency range of 0.1 Hz to 100 KHz.

3.1.3. Synthesis
The thioctic acid ferrocene derivative (20) used was synthesized and characterized as
described in section 2.2.2.
O

3.1.4. Cleaning and surface modification
3.1.5. Ellipsometry
The surfaces were first washed with MilliQ water, then 0.5 M H2SO4 for 1 min before
washing with MilliQ water again. The surfaces were then sonicated in ethanol for 2
mins. The clean surfaces were dried under nitrogen and incubated as described iin
sections 2.2.3-4. The thickness of the surfaces was then measured using ellipsometry.
3.1.6. Surface Plasmon resonance
The SPR experiment was carried out using gold SPR chips (see Figure 2.3) obtained
from GWC technologies. Gold SPR chips were rinsed with milliQ water and then
dried with nitrogen before modification
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3.1.7. Electrochemical cleaning and surface modification
Prior to experiments, the gold electrodes (2 mm diameter) were cleaned
electrochemically. The cleaned electrode surfaces were incubated in 4 mM ethanolic
solution o f the thioctic acid modified ferrocene amino acid derivative for 18 hrs at
room temperature. After 18hrs, the electrode surfaces were rinsed with ethanol and
sonicated in ethanol for another 10 mins before backfilling with 1 mM ethanolic
solution of hexanethiol for 5 mins.

The blocked electrode surfaces were then

activated with N-hydroxysuccinimide (NHS, 85 mg, 0.738 mmol) and l-ethyl-3-(3dimethylaminopropyl) carbodiimidehydrochloride (EDC.HC1, 32 mg, 0.167 mmol).
The modified surfaces were then characterised as described in section 2.1.6.
From the background-subtracted CV data (data not shown), the Coulombic charge was
obtained by integration, which allowed the determination of the surface coverage of
the redox-active probe according to the equation T= Q/nFA, where Q is the area of the
cathodic peak, n is the number of electrons involved in the Fc redox reaction (n = 1), F
is the Faraday’s constant, and A is the area o f the electrode. The surface coverage (T)
was calculated as 3.77 ± 0.9 xlO '

mol cm' after the formation of the SAM. The

surface coverage was estimated as 1.57 ± 0.3 xlO 11 mol cm"2 after backfilling with
hexanethiol. These values indicate a high quality packing o f the electrode surface."0
The surfaces were incubated in a solution of PSA specific peptide (50 mM phosphate
buffered solution, pH 8.0). The remaining active ester was quenched by incubation of
the peptide-modified electrode in ethanolic 100 mM ethanolamine solution for 10
mins at room temperature. Finally, the electrodes were washed with MilliQ water to
give the peptide-modified sensor surfaces.
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Results and discussion
The approach to the detection of PSA is shown in Figure 3.1. The biosensor approach
is based on the interaction of the peptide inhibitor to the target. The thioctic acid
portion o f the molecule facilitated immobilization on the gold surface. With the
ferrocene moiety close to the electrode surface, the interaction with PSA can be
monitored by the changes in the electronic response of the ferrocene before and after
modification.95 After the formation of the self assembled monolayer, the
electrochemical characteristics of the ferrocene modified surfaces were monitored
with respect to the concentration of PSA using cyclic voltammetry, square wave
voltammetry and electrochemical impedance spectroscopy.
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Scheme 3: Representation of the PSA sensor preparation. The electrode surface is
modified with a thioctic acid ferrocene derivative through Au-S linkages. The
electrode surface is the backfilled with hexanethiol before activation with EDC/NHS.
The peptide is then attached covalently to the electrode surface. The prepared
electrode surface is then used for the detection of PSA.

Prior to PSA analysis, a stock solution of PSA was prepared in the reconstituted assay
buffer (50 mM Tris-ClC>4 and 150 mM NaCl) at pH 7.8. After preparing the sensor
surface, the study of the interaction of the peptide with prostate specific antigen (PSA)
was carried out using EIS and SWV. The peptide modified surface was incubated in a
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solution o f PSA for 1 hour and the changes in the electrochemical signal were then
monitored.
From the cyclic voltammogram of the PSA specific peptide modified surface, it was
observed that the potential at which ferrocene is oxidized and reduced shifted to a
higher value, Table 3.1.
Table 3.1: Electrochemical properties of the sensor surface before PSA addition and
after PSA addition. Measurements were made in 50 mM Tris-C104 pH 7.8 buffered
solution with NaC104 as the supporting electrolyte. Values o f E1/2 and AE are in mV.
The values in parentheses represent the standard deviations from at least three
electrode measurements
Peptide

E°
524(9)

AE
40(3)

¡a/ ip
1.00(0.02)

PSA

531 (3)

43(5)

1.03(0.02)

This was attributed to the reduction in the solvent accessibility of the ferrocene and
also due to the increased difficulty in the oxidation and reduction of the ferrocene,
Figure 3.1. After the addition of PSA to the sensor surface, the changes became
difficult to measure with CV because o f its low sensitivity.

Figure 3.1: Left: cyclic voltammogram of the (a) electrode surface after the covalent
attachment of the PSA specific peptide on the electrode surface and (b) the same
electrode after immobilisation in Tris-C104 buffered solution of PSA. Right: the
corresponding square wave voltammogram before PSA modification and after PSA
modification.
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The electrode surfaces were then incubated in varying concentrations of PSA. The
SWV measurements were recorded in the absence o f the redox probe while E1S
measurements were obtained with 5 mM [Fe(CN)6]47[Fe(CN)6]3' and 0.1 mM NaC104
as the supporting electrolyte. From the SWV plots, Figure 3.2, the current density
decreased with the concentration of PSA. A dependence of potential with
concentrations was however not readily observed. This is probably due to the large
size of the PSA specific peptide and the ferrocene encapsulation in the protein
environment which leads to little or no changes in potential as the concentration of
PSA is increased. With SWV, the changes in current density were measurable until
the concentration of PSA is 25 pM at which point changes could not be detected in the
square wave voltamogram any longer.

Figure 3.2: SWV of the electrode surface after modification with (a) 0.1 (b) 2.5, (c)
10 and (d) 25 pM of PSA in Tris-C104 (50 mM, pH 7.8)

Impedance measurements were also recorded for the different concentrations of PSA.
Before the introduction of K3[(Fe(CN)6)]/ K4[(Fe(CN)6)], a high capacitive
comtribution was observed (see Figure 2.8). To obtain quantifiable results, an
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equivalent circuit was proposed, Figure 3.3, where Rs is the solution resistance, Q is
the constant phase element which is due to the inhomogeneity of the electrode surface,
W is Warburg impedance which is due the diffusion of the electroactive species in
solution and Rct is the charge transfer resistance. The impedance plots recorded before
and after modification with PSA were fitted to the same circuit. After fitting the data,
values were obtained from the equivalent circuit (Table 2.2).

Figure 3.3: Right: A Nyquist plot showing the addition o f different concentrations of
PSA after the addition of [a] 0.1 pM, [b] 2.5 pM, [c] 10 pM, [d] 50 pM and [e] 100
pM and Left: the equivalent circuit used to model the fit. The impedance experiments
were recorded in a Tris-C104 solution (50mM, pH 7.8) at an applied potential of 250
mV, modulation amplitude of 5mV and frequency range 0.1 Hz-100 kHz, using
K3[(Fe(CN)6)]/ K4[(Fe(CN)6)] as a solution based redox probe. Fittings to the
equivalent circuit are represented by solid lines.

A comparison of the Nyquist and Bode plot shows that the overall impedance of the
system increased as the concentration of PSA is increased. The solution resistance for
the 100 pM solution o f PSA seemed to have a higher value when compared to the
other concentration as shown in Figure 3.4. This trend is also observed in the table of
values obtained from the Nyquist plot.
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Frequency (Hz)

Figure 3.4: Bode plot (total impedance versus frequency) for PSA as the
concentration is increased from [►](). 1 pM, [ ^ ] 2.5 pM, [ • ] 10 pM, [®] 50 pM
and [■]100 pM. The plots were fitted to the same equivalent circuit as the Nyquist
plots.

From Table 3.2, it was observed that the resistance to charge transfer increased after
the modification of the electrode with PSA as expected because the peptide molecules
are now covering the surface of the electrode and it becomes difficult for the redox
probe to diffuse to the electrode surface.95,1,0
Table 3.2: Equivalent circuit values for the impedance measurement for PSA with Rs
and Ret in Ohmcm , Q in pSec cm' and W in mSsec cm' . The values in parentheses
represent the standard deviations from at least three electrode measurements
Rs

Q

n

Peptide

5.01 (0.12)

40.6(0.1)

0.93(0.01) 718(17)

7(0.01)

0.1 pM
2.5pM
lOpM
50 pM
100 pM

4.22(1.2)
4.44(1.6)
4.42(0.18)
4.22(1.5)
5.42(0.90)

40.0(0.4)
38.7(0.4)
23.8(0.1)
23.6 (0.3)
14.2 (0.2)

0.93(0.01)
0.90(0.02)
0.93(0.01)
0.88(0.03)
0.91(0.02)

7(0.01)
5(0.05)
7(0.01)
11(0.01)
3(0.01)
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Ret

889(21)
1145(68)
1162(132)
1640(223)
2118(34)

W

With the thickness of the adsorbed layer inversely proportional to the capacitance, the
capacitance of the system was observed to decrease with increase in charge transfer
resistance.
The plot of charge transfer resistance and PSA concentration was found to be linear in
the range 2.5-100 pM (slope = 9.868 i2-cm2pM"', R2 = 0.9983), Figure 3.5, with a
detection limit of 3.45 pM, estimated from 3(St/m), where Sb is the standard deviation
of the measurement signal for the blank and m is the slope of the analytical curve in
the linear region.
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Figure 3.5: A plot of charge transfer resistance (Ohms-cm2) versus the concentration
of PSA (picomolar). Error bars refer to the standard deviation.

This assay method has a linear range similar to that observed by Roberts et al83 and it
has a higher sensitivity compared to the detection limits of 3 ng/mL (88 pM) and 0.2
ng m l/1(6 pM) from the assay by Pampalakis84 and Zhao85 respectively.
As a proof of concept, the surfaces were also characterised by SPR and ellipsometry.
The refractive index of the protein was described by the Cauchy dispersion formula
(n= A + BA,2 + C/ X4 with the parameters A= 1.45, B= 0.01 and C= 0. Ellipsometry
62

analysis showed an increase in the ellipsometry angle which corresponds to the
adsorption of material to the gold surface.111

Figure 3.6: characteristic ellipsometric scan from the gold surface after modification
with compound 20, PSA specific peptide and PSA (lOOpM)

The SPR chip was modified with the PSA specific peptide as described in section
3.1.7. The modified chips were then mounted on the SPR imager and the assay buffer
was first flowed into the instrument. After attaining a steady signal, PSA was then
flowed into the system and the change in pixel intensity was monitored with time. The
change in pixel intensity was converted to % change in reflectivity which was
subsequently converted to thickness values using the Jung assumption.112
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Figure 3.7: SPR characteristic signal from the sensor surface after modification with
PSA(lOOpM)

The thickness for the PSA adlayer was found to be 137nm ± 13 by SPR this signifies
the formation of a multilayer. The measured ellipsometry data was fitted using the
Cauchy model. Thickness analysis by ellipsometry gave values of 226 ± 3.67 Á.
\
Conclusion
This chapter described the results of the detection o f prostate specific antigen using
electrochemical methods. The assay method can detect PSA with electrochemical
methods using its inhibitory peptide. The results also show a linear relationship
between the concentration of PSA and the charge transfer resistance in the range 2.5
to 100 pM which is comparable to previous assay methods. This approach to the
detection of PSA also has a lower detection limit when compared to previous assay
measurements with detection limits of 88 and 6 pM.

64

CHAPTER 4

SUMMARY AND FUTURE WORK
This work represents a successful attempt to detect the biomarkers for HCV and
prostate cancer. In this work, HCV NS3-4A protease was utilized to study hepatitis C
virus while PSA was used to study prostate cancer. Also in this study we utilized
ferrocene as our redox probe because of its electro-activity and also because
specificity is increased with the use of ferrocene since binding interactions with the
redox probe induce changes in the electrochemical signal which can be monitored and
measured. An inherent problem with using ferrocene as the only redox probe in
impedance measurements is that it increases the capacitive contribution to the
effective impedance. We were able to overcome this problem with the inclusion o f a
solution based redox probe which helped reduce the capacitive contribution and also
amplified the signal.
These studies show that PSA and HCV NS3-4A protease can be detected in the
picomolar range. The charge transfer resistance of PSA was found to have a linear
dependence on concentration in the range 2.5-100 pM and a detection limit of 3.45
pM. The HCV protease had a lower range of linearity, 10-50 pM, and a limit of
detection o f 14.8 pM. In the SWV analysis of PSA the ferrocene signal was no longer
observable at 25 pM concentration. This is probably due to the fact that the PSA
specific peptide is in itself a long peptide and further interaction with PSA may lead to
the ferrocene moiety being engulfed in this protein environment leading to loss of
redox signals. The SWV analysis of the HCV NS3-4A protease however showed a
linear correlation within the range 5-50 pM which is similar to the value obtained
from the impedance data. The approach developed was also observed to be very
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specific even in the presence of a contaminant like human serum albumin. The
thickness analysis for PSA and the HCV NS3-4A protease gave values of 226 ± 3.67

A and 224 ± 3.67 A respectively. This assay method is the first to detect the NS3-4A
and PSA using inhibitory peptide. This assay is more sensitive when compared with
other electrochemical techniques although less sensitive when compared to
commercial immunoassay methods (Tables 1.1 and 1.2).
These results lay the foundation for future work that is aimed at further developing
functioning biosensors. Work described in this thesis paves that way for detailed
biosensor work since it provides the fundamentals for the sensing approach and
demonstrates that the Fc-conjugates of the inhibitory peptides for NS3-4A and for
PSA exhibit reproducible modulations of the electrochemical properties upon addition
o f the target protein.
With our goal being to develop a device that can detect clinically important proteins
using this sensor approach, future work will include the detection of other proteins
using their inhibitory peptides some of which include; the human cytomegaloviral
protease using the M-site inhibitory peptide"5 (Gly-Val-Val-Asn-Ala-Ala-Cys-ArgLeu-Ala K, = 72 pM) and the human T-cell leukemia virus (Ac-Leu-Lys-Ala-Gln-IleHis-Phe Kj 50pM). The use of gold nanotube screen printed electrodes will also be
looked into as this will increase the sensitivity and ease of measurement. An array
chip that can detect these proteases at the same time will be fabricated. This array we
hope to develop into a device that can be utilized for clinical applications.
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A PPE N D IX

INTRODUCTION TO ELECTROCHEMISTRY
The detection of proteins can be carried out by optical (e.g. surface plasmon
resonance, ellipsometry) or electrochemical methods. Electrochemical methods offer
the advantage of being cheap, simple, fast and sensitive.

They can also provide

mechanistic information about the modification process. Electrochemistry is usually
the technique of choice when there is a need to monitor reactions occurring at an
electrode-electrolyte interface. To better understand the theories, the electrode
electrolyte interface is briefly discussed. When a potential is applied to an electrode
immersed in an electrolyte solution a potential difference develops at the interface
creating what is known as the electrical double layer as shown in Figure S 1

Figure SI: Representation of the electrical double layer. With the application of a
negative potential at the electrode surface, positive charges and solvated ions migrate
to the electrode surface forming the Helmholtz layers which increases into the
diffusion layer mostly populated by solvated ions. Figure reprinted with permission
from ref. 118
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In the absence of a redox couple, the double layer is capacitive in nature. With the
introduction of the redox couple, the double layer has both capacitive and resistive
components.
For a redox reaction:
O

+

n e'

■ ■■

~ ■

r

O is the oxidant, n is the number of electrons transferred, and R is its reduced product.
Charge transfer across the electrode/electrolyte interface leads to both faradaic and
non-faradaic components. The Faradaic component arises from the electron transfer
across the interface while the non-Faradaic current results from charging the double
layer capacitor. The current flowing at an electrified interface due to an
electrochemical reaction always contains non-Faradaic components, no matter how
well the measurement is made.119
Electrochemistry at the interface can be carried out using a redox probe in solution or
a surface active probe. For a redox probe in solution, diffusion of the electroactive
species to the electrode surface is significant and the process is said to be diffusion
controlled while for a surface active species electron transfer takes precedence. Some
of the methods used in studying this interfacial reaction are discussed below.
For the purpose of this research, some electrochemical methods as well as optical
methods of detection will be briefly discussed.
CYCLIC VOLTAMMETRY
Cyclic voltammetry (CV) is probably the most widely used technique in
electrochemistry. It is an electrochemical technique that has found usefulness in
several areas of analysis because it does not require sophisticated instrumentation and
a lot o f information about redox reactions can be easily obtained and interpreted. In
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CV, the potential of a small, stationary working electrode is changed linearly with
time starting from a potential where no electrode reaction occurs and moving to
potentials where reduction or oxidation of a solute (the material being studied) occurs.
After traversing the potential region in which one or more electrode reactions take
place, the direction of the linear sweep is reversed and the electrode reaction of
intermediates and products formed during the forward scan can then be detected.

190

CV is a powerful tool for the determination of formal redox potentials (the average of
the anodic and cathodic peak potentials), peak separation (AEP), chemical reactions
that proceed or follow the electrochemical reaction of interest and evaluation of
electron transfer kinetics. A typical voltammogram is shown in Figure S2

Figure S2: Cyclic voltammogram showing the anodic and cathodic peak currents as
well as the anodic and cathodic peak potentials. Adapted from ref. 121
The relationship between the scan rate and the peak current is expressed in the
Randles Sevcik equation.119
ip = (269,000)nm ADmcvm
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where ip is the peak current in Amps, n is the number of electrons, A is the area of the
electrode in cm , D is the diffusion coefficient in cm s ' , c the concentration in molcm'
3 and v is scan rate in Vs'1. For redox species adsorbed on the electrode surface, the
Faradaic current is directly proportional to the scan rate and the ratio of the anodic and
cathodic current peaks is usually unity while for a solution based redox probe, the
current is proportional to the square root of the scan rate.

SQUARE WAVE VOLTAMMETRY
Square wave voltammetry (SWV) is an important electroanalytical method. Compared
to both linear sweep and cyclic voltammetry, square wave voltammetry has a much
broader dynamic range and lower limit of detection because of its efficient
discrimination of capacitance current. In SWV, a potential waveform is applied to the
electrode; pairs of current measurements are then made (ti and ti) for each cycle as
shown in Figure S3. The difference current response in a square wave is proportional
to the square wave frequency
idifr = nFAcD1/2f 1/2
where n is the number of electrons, F is the Faraday constant, A is the electrode area, c
is the bulk concentration of the redox active species, D is the diffusion coefficient and
f is the square wave frequency.
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Figure S3: A typical potential time profile in a square wave voltammetry experiment
showing the square wave amplitudes and the corresponding electrochemical signal.
Image reprinted with permission from ref. 122

The square wave amplitude Esw is equal to one half of the peak to peak amplitude and
the potential increment AE is the step height of the waveform. For practical analysis,
SWV is generally the best choice among all pulse methods, because it offers
background suppression, high sensitivity, faster scan times, and it is applicable to a
wider range of electrode materials and systems.119 Square wave voltammetry has been
applied in several studies.

ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY
Electrochemical impedance spectroscopy (EIS) is a non-destructive method used to
probe the relaxation phenomena over a range of frequencies. EIS measures the
frequency response of a system by measuring the impedance, Z. This impedance can
be calculated from the component impedance.119
Z (w) —Zre - jZ im
Zre and Zim are the real and the imaginary components of the impedance. A
representation o f the impedance plot is depicted in Figure S4. This is achieved by
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applying a small alternating current signal over a range of frequencies at a specified
potential. When charge transfer takes place at the interface, the mass transports of the
reactant and product take on roles in determining the rate of electron transfer, which
depends on the consumption of the oxidants and the production of the reductant near
the electrode surface. The mass transport of the reactants and the products provides
another class o f impedance ( W), aside from the resistance to charge transfer, known as
Warburg impedance.

Figure S4: Sample Nyguist plot and the corresponding equivalent circuit. Zjm and Zre
represent the capacitive and resistive components of the system, Rs is the solution
resistance, Q is the constant phase element, Rct is the resistance to charge transfer and
W is the Warburg impedance. Adapted from ref. 126

The electrochemical signal is then modelled using an equivalent circuit the elements
of which can give information about the kinetics at the electrode surface. Varying the
frequency changes the relative contribution of each of the elements in the equivalent
circuit to the overall impedance. Measuring impedances over a wide range of
frequencies allows the value of each individual element of the equivalent circuit to be
determined.119
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300-

Figure S5: A Nyquist plot showing the surface modified with the Hep CV NS3-4A
specific peptide [►] and after the addition of 100 pM [■] of the protease. The
impedance experiments were recorded in a Tris-C104 solution (20mM, pH 8) at an
applied potential of 40Mv, modulation amplitude of 5mV and frequency range 0.1 Hz100 kHz, using K4[Fe(CN)6]/K3[Fe(CN)6] as a solution based redox probe Fittings to
the equivalent circuit are represented by solid lines.
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Figure S6: Left: A Nyquist plot showing the surface modified with the HCV NS3-4A
specific peptide [►] and after the addition of 5 pM [■] of the NS3-4A protease. The
impedance experiments were recorded in Tris-CK)4 solution (20mM, pH 8) at an
applied potential of 250mV, modulation amplitude of 5mV and frequency range
O.lHz-lOO kHz, using K4[Fe(CN)6]/K3[Fe(CN)6] as a solution based redox probe.
Fittings to the equivalent circuit are represented by solid lines. Right: the
corresponding square wave voltammogram.

chem ical shift (ppm)

Figure S7 : Partial 'HNMR of (Boc)NHFcCOOMe (22)) in CDC13
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chemical shift (ppm)

Figure S8: Partial ]HNMR of (Thc)NHFcCOOMe (23)) in CDC13

ch e m ical sh ift ppm

Figure S9: Partial ‘HNMR of (Thc)NHFcCOOH (21) in CD3OD
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chemical shift (ppm)
Figure S10: Partial ‘HNMR of (Thc)NHFcCOOH (21) in DMSO-dg

Generated and Experimental

Figure SI 1: Characteristic ellipsometric scan for the bare gold surface
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Generated and Experimental

Figure S12: Characteristic ellipsometric scan for the bare gold surface after
modification with peptide.
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